The challenge of sodium-glucose cotransporter type 2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Does their efficacy outweigh infectious risks?

J Visc Surg. 2024 Jun;161(3):159-160. doi: 10.1016/j.jviscsurg.2024.01.001. Epub 2024 Feb 5.

Authors

Anne-Cécile Ezanno¹, Pierre-Louis Conan², Cyril Garcia³

Affiliations

¹ Digestive surgery department, HIA Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France. Electronic address: [email protected].
² Department of infectious diseases, HIA Bégin, 94160 Saint-Mandé, France.
³ Endocrinology department, HIA Bégin, 94160 Saint-Mandé, France; Val de Grace School, Army health service, 75005 Paris, France.

PMID: 38320952
DOI: 10.1016/j.jviscsurg.2024.01.001

No abstract available

Keywords: Antihyperglycemic drugs; Diabetes; Fournier gangrene; Surgery.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Treatment Outcome

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents